Cargando…

Validation of a bladder symptom screening tool in women with incontinence due to overactive bladder

INTRODUCTION AND HYPOTHESIS: The Actionable Bladder Symptom Screening Tool (ABSST) was initially developed to identify patients with multiple sclerosis (MS) who could benefit from lower urinary tract assessment and treatment. Assessment of the measurement properties of the ABSST, including its abili...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cardozo, Linda, Staskin, David, Currie, Brooke, Wiklund, Ingela, Globe, Denise, Signori, Manuel, Dmochowski, Roger, MacDiarmid, Scott, Nitti, Victor W., Noblett, Karen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer London 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4234889/ https://www.ncbi.nlm.nih.gov/pubmed/24859795 http://dx.doi.org/10.1007/s00192-014-2417-7

Ejemplares similares

Percutaneous Tibial Nerve Stimulation: A Clinically and Cost Effective Addition to the Overactive Bladder Algorithm of Care
por: Staskin, David R., et al.
Publicado: (2012)

Development of a short form and scoring algorithm from the validated actionable bladder symptom screening tool
por: Bates, David, et al.
Publicado: (2013)

Comment on: update on the management of overactive bladder
por: Staskin, David
Publicado: (2022)

Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add‐on mirabegron therapy to solifenacin (BESIDE)
por: Drake, Marcus J., et al.
Publicado: (2017)

Modeling dose-response relationships of the effects of fesoterodine in patients with overactive bladder
por: Cardozo, Linda, et al.
Publicado: (2010)

Six-Month Outcomes of Reimplantation of a Coin-Sized Tibial Nerve Stimulator for the Treatment of Overactive Bladder Syndrome With Urgency Urinary Incontinence
por: Kaaki, Bilal, et al.
Publicado: (2022)

Taking OAB seriously: A qualitative evaluation of primary care education on overactive bladder syndrome management
por: Turell, Wendy, et al.
Publicado: (2020)

Update on the management of overactive bladder: patient considerations and adherence
por: Gomelsky, Alex, et al.
Publicado: (2010)

Fesoterodine for the treatment of urinary incontinence and overactive bladder
por: Ellsworth, Pamela
Publicado: (2009)

Development of oxybutynin chloride topical gel for overactive bladder
por: Lucente, Vincent R, et al.
Publicado: (2011)

Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: a review of published evidence
por: Campbell, Jonathan D, et al.
Publicado: (2009)

Initial clinical experience with selective bladder denervation for refractory overactive bladder
por: Tu, Le Mai, et al.
Publicado: (2018)

OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder
por: Sievert, K-D, et al.
Publicado: (2014)

Mirabegron in the Management of Overactive Bladder Syndrome
por: O’Kane, Miriam, et al.
Publicado: (2022)

Recent advances in managing overactive bladder
por: Araklitis, George, et al.
Publicado: (2020)

An Evaluation of the Efficacy and Safety of Vibegron in the Treatment of Overactive Bladder
por: Frankel, Jeffrey, et al.
Publicado: (2022)

Cognitive Effects of Anticholinergic Load in Women with Overactive Bladder
por: Araklitis, George, et al.
Publicado: (2020)

Socioeconomic Costs of Overactive Bladder and Stress Urinary Incontinence in Korea
por: Sung, Wooseuk, et al.
Publicado: (2012)

Impact of smoking habit on overactive bladder symptoms and incontinence in women
por: Kawahara, Takashi, et al.
Publicado: (2020)

Female Functional Constipation Is Associated with Overactive Bladder Symptoms and Urinary Incontinence
por: Maeda, Takahiro, et al.
Publicado: (2017)

Vibegron improves quality‐of‐life measures in patients with overactive bladder: Patient‐reported outcomes from the EMPOWUR study
por: Frankel, Jeffrey, et al.
Publicado: (2021)

Adherence to Overactive Bladder Syndrome Treatments Recent Developments and Future Perspectives
por: Robinson, Dudley, et al.
Publicado: (2023)

Overactive bladder
por: Wallace, Karen M., et al.
Publicado: (2015)

Treatment of neurogenic detrusor overactivity and overactive bladder with Botox (onabotulinumtoxinA): Development, insights, and impact
por: Nitti, Victor, et al.
Publicado: (2023)

Understanding overactive bladder and urgency incontinence: what does the brain have to do with it?
por: Smith, Ariana L.
Publicado: (2018)

The effect of vitamin D deficiency in children with overactive bladder related urinary incontinence
por: Özçift, Burak, et al.
Publicado: (2022)

Toileting behaviors, urinary cues, overactive bladder, and urinary incontinence in older women
por: O’Connell, Kathleen A., et al.
Publicado: (2022)

Health Resource Utilization and Cost for Patients with Incontinent Overactive Bladder Treated with Anticholinergics
por: Yehoshua, Alon, et al.
Publicado: (2016)

Interpretation of the Meaningfulness of Symptom Reduction with Vibegron in Patients with Overactive Bladder: Analyses from EMPOWUR
por: Frankel, Jeffrey, et al.
Publicado: (2021)

Health-related quality of life and economic impact of urinary incontinence due to detrusor overactivity associated with a neurologic condition: a systematic review
por: Tapia, Crisanta I, et al.
Publicado: (2013)

The relationship between depression and overactive bladder/urinary incontinence symptoms in the clinical OAB population
por: Lai, H. Henry, et al.
Publicado: (2016)

Postmenopausal overactive bladder
por: Tomaszewski, Jacek
Publicado: (2014)

Vibegron for the Treatment of Patients with Dry and Wet Overactive Bladder: A Subgroup Analysis from the EMPOWUR Trial
por: Staskin, David, et al.
Publicado: (2022)

Patient and Clinician Challenges with Anticholinergic Step Therapy in the Treatment of Overactive Bladder: A Narrative Review
por: Dmochowski, Roger R., et al.
Publicado: (2023)

Plain language summary of safety and symptom improvement with vibegron in people with overactive bladder: results from the EMPOWUR study
por: Staskin, David, et al.
Publicado: (2023)

Solifenacin significantly improves all symptoms of overactive bladder syndrome
por: CHAPPLE, C R, et al.
Publicado: (2006)

A healthy bladder: a consensus statement
por: Lukacz, E S, et al.
Publicado: (2011)

Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo
por: Van Kerrebroeck, Philip EV, et al.
Publicado: (2009)

Urodynamic and Bladder Diary Factors Predict Overactive Bladder-wet in Women: A Comparison With Overactive Bladder-dry
por: Hsiao, Sheng-Mou, et al.
Publicado: (2019)

Practical aspects of lifestyle modifications and behavioural interventions in the treatment of overactive bladder and urgency urinary incontinence
por: Wyman, J F, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_jrbvprnr4rg9tfhnn4aeuckshr